Skip to main content
OpenTrials
Completed

NCT Number: NCT06259383

Oral Ivermectin for Chikungunya Viral Infection

Chikungunya viral infection (CVI) is a mosquito-borne infection, caused by chikungunya virus (CHIKV), an alphavirus, belonging to the family Togaviridae. This infection causes febrile illness associated with high fever, rash, acute deliberating and persistent arthralgia. There is no licensed vaccine or specific treatment for this infection. Ivermectin (IVM), commonly-used antiparasitic, has been demonstrated to inhibit replication of CHIKV.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Clinical Syndrome

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Prince of Songkla University

Hat Yai, Changwat Songkhla, 90110, Thailand

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • patients with virologic confirmation of chikungunya infection who had symptoms less than 72 hours prior to visit

Exclusion criteria

  • patients with virologic confirmation of chikungunya infection who had symptoms more than 72 hours prior to visit

Treatment and study plan

Ivermectin

Drug

3-day 1 daily dose of 400 μg/kg oral ivermectin

Primary outcomes

  1. Day of fever clearance

    Time frame: 1 week

    120 participants would be under Body Temperature Assessment - the staff would assess once daily until the fever clearance was below 38C and the measure proportion of patients with fever clearance in each day of assessment until fever clearance at least in 7 days

Secondary outcomes

  1. Day of virologic clearance

    Time frame: 1 week

    120 participants would be obtained blood examination for virological testing every day until virological clearance at least in 7 days

Sponsors and collaborators

Lead sponsor

Prince of Songkla University

Other

Registry information

Official study title

A Randomized Controlled Trial of Oral Ivermectin for Patients With Chikungunya Viral Infection During Urban Outbreak in Southern Thailand

Important dates

Study start
2018
Primary completion
2021
Study completion
2024
First posted
Feb 14, 2024
Registry last updated
Feb 14, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.